TLDR The equine epididymis mainly uses type 1 5α-reductase, and both finasteride and dutasteride can inhibit its activity.
The study investigated 5α-reductase activity and expression in the epididymis of stallions, focusing on the conversion of progesterone and testosterone to DHP and DHT. It found that the type 1 isoform of 5α-reductase predominated in the equine epididymis, while the type 2 isoform was not detected. Both finasteride and dutasteride effectively inhibited 5α-reductase activity. The study also explored pregnenolone as a potential substrate but found no evidence supporting its direct metabolism by equine 5α-reductases. This research provided insights into the enzymatic processes in the equine epididymis, contributing to the understanding of steroid metabolism in horses.
13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
193 citations
,
August 1985 in “Endocrinology” Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
19 citations
,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
June 2019 in “Journal of Drug Delivery and Therapeutics” Finasteride effectively treats hair loss and prostate issues with minimal side effects.
65 citations
,
October 1999 in “Journal of The American Academy of Dermatology” Finasteride effectively reduces hair loss by decreasing androgen levels.
60 citations
,
December 1998 in “Clinical Pharmacology & Therapeutics” Both drugs lower DHT levels, with GI198745 being more effective.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” 61 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism”
